Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD

Journal of the American Society of Nephrology

Volumn 22, Issue 4, 2011, Pages 664-672

  Zhang, Qian ^a   Qiu, Junsi ^a   Li, Haiming ^a   Lu, Yanwen ^a   Wang, Xiaoyun ^b   Yang, Junwei ^c   Wang, Shaoqing ^a   Zhang, Liyin ^a   Gu, Yong ^a   Hao, Chuan Ming ^a,d   Chen, Jing ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLINE; CYCLOOXYGENASE 2; PARATHYROID HORMONE; PHOSPHATE; PROSTAGLANDIN E2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 79953308460     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010060594     Document Type: Article

References (57)

1. Parfitt AM: The hyperparathyroidism of chronic renal failure: A disorder of growth. Kidney Int 52: 3-9, 1997
2. Gonzalez EA, Martin KJ: Renal osteodystrophy: Pathogenesis and management. Nephrol Dial Transplant 10[Suppl 3]: 13-21, 1995
3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000 (Pubitemid 30318271)
4. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68: 221-228, 1994 (Pubitemid 24289741)
5. Katoh N, Nakayama M, Shigematsu T, Yamamoto H, Sano K, Saito I, Nakano H, Kasai K, Kubo H, Sakai S, Kawaguchi Y, Hosoya T: Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 35: 465-468, 2000
6. Wang Q, Palnitkar S, Parfitt AM: The basal rate of cell proliferation in normal human parathyroid tissue: Implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol (Oxf) 46: 343-349, 1997
7. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786-1793, 1995
8. Silver J, Kilav R, Naveh-Many T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 283: F367-F376, 2002
9. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95: 2047-2053, 1995
10. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H: Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20: 744-750; discussion 750-752, 1996
11. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H: Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55: 1375-1383, 1999 (Pubitemid 29157136)
12. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443, 1993 (Pubitemid 23273922)
13. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598-1606, 1996
14. Goodman WG, Quarles LD: Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 74: 276-288, 2008 (Pubitemid 352001233)
15. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H: Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62: 1196-1207, 2002
16. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS: p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60: 2109-2117, 2001 (Pubitemid 33070454)
17. Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, Lu Y, Tominaga Y, Cannata-Andia J, Slatopolsky E, Dusso AS: EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol 19: 310-320, 2008 (Pubitemid 351240653)
18. Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E: 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: A mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J Steroid Biochem Mol Biol 89-90: 507-511, 2004 (Pubitemid 38844339)
19. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996 (Pubitemid 27010118)
20. Mann JR, Backlund MG, DuBois RN: Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2: 202-210, 2005 (Pubitemid 40812470)
21. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872, 1991
22. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K: Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001 (Pubitemid 33586867)
23. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009
24. Brown EM, Swartz SL: Production of prostaglandins by dispersed cells and fragments from bovine parathyroid glands. Prostaglandins 29: 35-46, 1985 (Pubitemid 15196144)
25. Bell CD, Vidal S, Kovacs K, Anderson J, Rotondo F: Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland. Endocr Pathol 15: 29-38, 2004 (Pubitemid 38951806)
26. Gardner DG, Brown EM, Attie MF, Aurbach GD: Prostaglandin-mediated stimulation of adenosine 3′,5′-monophosphate accumulation and parathyroid hormone release in dispersed human parathyroid cells. J Clin Endocrinol Metab 51: 20-25, 1980 (Pubitemid 10009231)
27. Gardner DG, Brown EM, Windeck R, Aurbach GD: Prostaglandin E2 stimulation of adenosine 3′,5′-monophosphate accumulation and parathyroid hormone release in dispersed bovine parathyroid cells. Endocrinology 103: 577-582, 1978 (Pubitemid 8393738)
28. Krause MW, Hedinger CE: Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 16: 772-784, 1985 (Pubitemid 15040812)
29. Yamaguchi S, Yachiku S, Morikawa M: Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab 82: 2681-2688, 1997 (Pubitemid 27337894)
30. Ohta K, Manabe T, Katagiri M, Harada T: Expression of proliferating cell nuclear antigens in parathyroid glands of renal hyperparathyroidism. World J Surg 18: 625-628; discussion 628-629, 1994
31. Muller-Decker K, Furstenberger G: The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 46: 705-710, 2007 (Pubitemid 47255191)
32. Bourdeau A, Souberbielle JC, Bonnet P, Herviaux P, Sachs C, Lieberherr M: Phospholipase-A2 action and arachidonic acid metabolism in calcium-mediated parathyroid hormone secretion. Endocrinology 130: 1339-1344, 1992
33. Bourdeau A, Moutahir M, Souberbielle JC, Bonnet P, Herviaux P, Sachs C, Lieberherr M: Effects of lipoxygenase products of arachidonate metabolism on parathyroid hormone secretion. Endocrinology 135: 1109-1112, 1994 (Pubitemid 24271205)
34. Almaden Y, Canalejo A, Ballesteros E, Anon G, Rodriguez M: Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 11: 1712-1718, 2000
35. Canalejo A, Canadillas S, Ballesteros E, Rodriguez M, Almaden Y: Importance of arachidonic acid as a mediator of parathyroid gland response. Kidney Int Suppl Jun: S10-S13, 2003 (Pubitemid 36605854)
36. Canadillas S, Canalejo R, Rodriguez-Ortiz ME, Martinez-Moreno JM, Estepa JC, Zafra R, Perez J, Munoz-Castaneda JR, Canalejo A, Rodriguez M, Almaden Y: Upregulation of parathyroid VDR expression by extracellular calcium is mediated by ERK1/2-MAPK signaling pathway. Am J Physiol Renal Physiol 298: F1197-F1204, 2010
37. Denda M, Finch J, Slatopolsky E: Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28: 596-602, 1996 (Pubitemid 26337601)
38. Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC: Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67: 888-896, 2007 (Pubitemid 46215892)
39. Chang CL, Ma B, Pang X, Wu TC, Hung CF: Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther 17: 1365-1372, 2009
40. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744, 2001
41. Dovedi SJ, Kirby JA, Davies BR, Leung H, Kelly JD: Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol 54: 621-630, 2008
42. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T, Koichi M: A COX-2 inhibitor prevents the esophageal inflammation-metaplasia- adenocarcinoma sequence in rats. Carcinogenesis 26: 565-570, 2005 (Pubitemid 41214145)
43. Wang JL, Cheng HF, Shappell S, Harris RC: A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57: 2334-2342, 2000 (Pubitemid 30340732)
44. Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, Zatz R: Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 64: 2172-2181, 2003 (Pubitemid 37449552)
45. Sanchez PL, Salgado LM, Ferreri NR, Escalante B: Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848-853, 1999 (Pubitemid 29501311)
46. Hao CM, Breyer MD: Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70: 357-377, 2008
47. Turini ME, DuBois RN: Cyclooxygenase-2: A therapeutic target. Annu Rev Med 53: 35-57, 2002 (Pubitemid 34177870)
48. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors: Subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001 (Pubitemid 32385902)
49. Gardner DG, Brown EM, Windeck R, Aurbach GD: Prostaglandin F2alpha inhibits 3′,3′-adenosine monophosphate accumulation and parathyroid hormone release from dispersed bovine parathyroid cells. Endocrinology 104: 1-7, 1979 (Pubitemid 9084579)
50. Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E: Pathogenic mechanisms for parathyroid hyperplasia. Kidney Int Suppl Jul: S8-S11, 2006 (Pubitemid 43992869)
51. Tian M, Schiemann WP: PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J 24: 1105-1116, 2010
52. Spinella F, Rosano L, Di Castro V, Nicotra MR, Natali PG, Bagnato A: Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res 10: 4670-4679, 2004 (Pubitemid 38955517)
53. Fujii Y, Moreira JE, Orlando C, Maggi M, Aurbach GD, Brandi ML, Sakaguchi K: Endothelin as an autocrine factor in the regulation of parathyroid cells. Proc Natl Acad Sci U S A 88: 4235-4239, 1991 (Pubitemid 21914514)
54. Shvil Y, Naveh-Many T, Barach P, Silver J: Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1: 99-104, 1990
55. Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 15: 2579-2587, 2004 (Pubitemid 41103364)
56. Takahashi F, Denda M, Finch JL, Brown AJ, Slatopolsky E: Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int 61: 1332-1338, 2002 (Pubitemid 34304494)
57. Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M: Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 16: 1870-1878, 2001